Ipilimumab (Specialist drug)

How it works

It is a monoclonal antibody against CTLA-4 that removes a key brake on T-cell activation, enhancing antitumour immune responses.

Prescribing in practice

• Immune-related adverse events affecting the bowel, liver, skin, endocrine glands and joints can be severe and the cornerstone of management is prompt recognition and corticosteroid or immunosuppressive treatment.
• Endocrinopathies such as hypophysitis, thyroid dysfunction and adrenal insufficiency may present non-specifically and require a high index of suspicion.
• Immune toxicities can arise during or long after treatment, so co-prescribing and inter-specialty communication must account for delayed effects.

Monitoring

Monitor liver, thyroid and other endocrine function and watch for colitis, dermatitis and arthritis throughout and after treatment, guided by the SPC and oncology protocols.

Counselling the patient

• Report new diarrhoea, rashes, fatigue or joint swelling without delay.
• Do not start steroids or other immune medicines without informing your oncology team.
• Immune side effects can appear weeks or months after dosing.

Evidence & guidelines

Randomised trials in advanced melanoma demonstrate improved overall survival, and the immune-related arthritis it provokes is well described in rheumatology literature.